NextCure Current Ratio 2018-2021 | NXTC

NextCure current ratio from 2018 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
NextCure Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.26B $0.01B 30.20
2021-03-31 $0.27B $0.01B 33.35
2020-12-31 $0.29B $0.01B 27.89
2020-09-30 $0.30B $0.01B 51.73
2020-06-30 $0.32B $0.01B 37.68
2020-03-31 $0.33B $0.01B 40.07
2019-12-31 $0.34B $0.02B 22.60
2019-09-30 $0.19B $0.01B 15.00
2019-06-30 $0.20B $0.01B 17.05
2019-03-31 $0.13B $0.01B 12.77
2018-12-31 $0.14B $0.01B 13.19
2018-09-30 $0.00B 0.00
2018-06-30 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-12-31 $0.01B $0.00B 3.02
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.213B $0.022B
NextCure Inc. is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company's product candidate consists of NC318 and NC410 which are in clinical stage. NextCure Inc. is based in Beltsville, Maryland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86